Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden.
about
Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritisEpidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factorsIs nephrolithiasis an unrecognized extra-articular manifestation in ankylosing spondylitis? A prospective population-based Swedish national cohort study with matched general population comparator subjectsCase definitions in Swedish register data to identify systemic lupus erythematosus.The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.Accelerating translational research by clinically driven development of an informatics platform--a case study.Validation of the rheumatoid arthritis diagnosis in the Swedish National Patient Register: a cohort study from Stockholm County.Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register studyPostmenopausal hormone therapy and the risk of rheumatoid arthritis: results from the Swedish EIRA population-based case-control study.The microbiome and rheumatoid arthritisLong term alcohol intake and risk of rheumatoid arthritis in women: a population based cohort studyElevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study.Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.What is the prevalence of musculoskeletal problems in the elderly population in developed countries? A systematic critical literature review.Early menopause and severity of rheumatoid arthritis in women older than 45 years.Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition.Implementation of the CDC translational informatics platform--from genetic variants to the national Swedish Rheumatology Quality RegisterAmbient air pollution exposures and risk of rheumatoid arthritis: results from the Swedish EIRA case-control studyAmbient air pollution exposures and risk of rheumatoid arthritis.Incidence and prevalence of gout in Western Sweden.Concentration of antibodies against Porphyromonas gingivalis is increased before the onset of symptoms of rheumatoid arthritis.Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort studyHigh-specificity bioinformatics framework for epigenomic profiling of discordant twins reveals specific and shared markers for ACPA and ACPA-positive rheumatoid arthritis.Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort study.Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.A nationwide cross-sectional overview of patients with rheumatoid arthritis followed in outpatient specialty clinics in Finland.Does disease activity at start of biologic therapy influence work-loss in RA patients?The epidemiology of rheumatoid arthritis in Ontario, Canada.Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden.Effects of aerobic and muscle strengthening exercise in adults with rheumatoid arthritis: a narrative review summarising a chapter in Physical activity in the prevention and treatment of disease (FYSS 2016).Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force.Treatment of rheumatoid arthritis during pregnancy: present and future.The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting.Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands.How well do ACPA discriminate and predict RA in the general population: a study based on 12 590 population-representative Swedish twins.Rheumatoid arthritis is still expensive in the new decade: a comparison between two early RA cohorts, diagnosed 1996-98 and 2006-09.What is the impact of chronic systemic inflammation such as rheumatoid arthritis on mortality following cancer?Does disease activity at the start of biologic therapy influence health care costs in patients with RA?The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients.
P2860
Q21134808-416EFB8A-CB5D-4EE3-874A-32C020A62570Q27685556-3D66B96B-CC9C-4431-860B-75A6D8C3A530Q28545171-F327042B-F28B-4867-9597-822D184C3D62Q31034949-0421A1D1-D12B-4D66-9BC7-57E376429A1FQ33892790-AAFEE375-4F23-4FA8-B27D-382EA11C8C97Q34155502-CF5C6F94-C5F7-435F-9897-1D5ECAF8761EQ34996377-79A4D2D5-E98E-4E1A-BD67-B650DC483D86Q35048347-9A0E81B5-B74B-4825-BAC7-67BFFC3C3013Q35585070-E931338E-3958-4A3A-BECF-8AEF4B782FFBQ35689433-C9E162AE-C6C8-4B6F-BA39-F22281C6ED11Q35743863-46B77D21-3A2A-4445-BEE6-3584F931BE29Q36087085-43051B2F-3252-428D-9875-43D3C302023EQ36213507-B623AE84-F8E4-4D8E-B2D1-F3A57528B559Q36220832-1CBEFDE9-F28B-4C9A-A7C1-B01E20B2D7B9Q36427360-8B88A383-0B4D-40C0-A994-50625CD256CBQ36633422-501BC23E-3E07-412B-B4F1-A5ED0CC65AF8Q36694143-6431C33D-4BC0-4656-830E-7C8116B426D7Q36758706-80D100F3-FC31-4B37-AC70-A1B3552F0833Q36844067-D065594E-79FF-40DB-B1B1-9A6CC236CBEBQ36859711-CFFE7A2F-21A1-488F-A9E3-9D518E673157Q37093885-477D23B3-29A9-4493-975D-08D90539B42DQ37240538-3D43EE3E-4943-499F-A134-9952A08F1344Q37341911-0C6B2348-076B-41BB-A1A0-54F3897BD640Q37431833-52CD19E0-AB45-47E2-B58D-FB4535E22E88Q37658783-65A62152-E5F4-48BF-B129-BF6125BBA23FQ37838346-31C12F0C-548B-4D58-9A47-059C5042BF05Q38198117-FC69A047-9483-4116-A822-81FD8EEAB217Q38410704-3210AE3A-A2F3-49D9-847E-3D0170673B33Q38420988-E76953F4-D4FD-4A2C-B2D5-5C8A7F694034Q38533964-BA48EB69-D051-4B09-8AAD-4E6C3F1996ECQ38722375-4D8DC58F-FE4C-4A67-8C44-7351D31DDC3CQ38757421-2D807C64-6C18-4C9C-BBEB-E4B34F945D57Q38832618-18A982B9-2157-459F-8D6F-9A0D0C753457Q39029106-EA5D698D-6545-4A57-967D-2918A443A985Q39043798-CE26A587-A8F1-4610-B876-5DE707AD43C8Q39812962-C8881C55-185D-4655-85E4-00F93DE5BDABQ40015472-1B5F722A-B9BE-4A63-BD9A-E64F6AEBF4ACQ40967649-5EC3131F-79D1-453E-B58C-0B2A9D552911Q41183360-013693B6-B913-4FAE-B686-926C7C4D9289Q41471703-CC44DC8F-D44A-4570-81B0-D8ED7B8A0926
P2860
Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Nationwide prevalence of rheum ...... ase-modifying drugs in Sweden.
@en
Nationwide prevalence of rheum ...... ase-modifying drugs in Sweden.
@nl
type
label
Nationwide prevalence of rheum ...... ase-modifying drugs in Sweden.
@en
Nationwide prevalence of rheum ...... ase-modifying drugs in Sweden.
@nl
prefLabel
Nationwide prevalence of rheum ...... ase-modifying drugs in Sweden.
@en
Nationwide prevalence of rheum ...... ase-modifying drugs in Sweden.
@nl
P356
P1476
Nationwide prevalence of rheum ...... ase-modifying drugs in Sweden.
@en
P2093
ARTIS study group
Johan Askling
P304
P356
10.1136/ARD.2010.133371
P407
P577
2010-12-13T00:00:00Z